Corgenix Announces Collaboration With SpectraCell Laboratories (PR Newswire via Yahoo! Finance)

Posted on July 29, 2008

Under terms of the relationship Corgenix’ AspirinWorks® product will be used to assess aspirin effect since part of SpectraCell’sitting broad cardiovascular dare to undertake assessment services.

“SpectraCell is increasingly recognized as a major lab in the U.S. for individualized cardiovascular testing and risk assessment. Their unique be nearly equal to cardiovascular medicine provides a perfect fit since aspirin effect testing,” said Douglass Simpson, Corgenix’ President and Chief Executive Officer. “This new association, combined by their physician-directed sales vigor, is an important step towards Corgenix, and we look forward to a long-term relationship.”

The collaboration will allow SpectraCell to take advantage of Corgenix’ unique diagnostic assay that determines the effect of aspirin on platelets in apparently healthy individuals by dint of. measuring the level of thromboxane production (aspirin’s mark). The higher the levels of thromboxane, the stickier the blood platelets, and the less impact the aspirin is having. Clinical studies suggest that more than 25 percent of all patients taking aspirin are not sufficiently protected from suffering a cardiovascular event.

“This arrangement further expands our functional testing capabilities to include aspirin effect,” said Dr. Fred Crawford, VP of Operations and Technical Director at SpectraCell Laboratories. “Partnering with Corgenix helps insure that SpectraCell continues to deliver the most advanced technology and highest quality useful office to our medical man clients nationwide.”

Physicians interested in learning more concerning SpectraCell’s advanced clinical testing may call 800-227-5227 or e-mail info@spectracell.com.

About Corgenix Medical Corporation

Corgenix is a leader in the growth and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders, including the world’session single non-blood-based test for aspirin non-responsiveness. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The gathering commonly sells over 50 diagnostic products through a global distribution reticulated. More information is available at http://www.corgenix.com.

About SpectraCell Laboratories

SpectraCell is a CLIA accredited laboratory that services healthcare providers nationwide by providing an innovative assessment of a patient’s nutritional and cardiovascular status. Unlike traditional serum, hair and urine tests, SpectraCell’s patented FIA(TM) (Functional Intracellular Analysis) measures how an individual’s white blood cells respond to varied environments of vitamins, minerals, amino acids and antioxidants. By evaluating the functionality of specific nutrients in a patient’s own cells, individual differences in metabolism, age, genetics, health, prescription drug usage, absorption rate or other factors are taken into consideration, opportunity a true “window put on intracellular function.” Unlike traditional cholesterol tests, SpectraCell’s LPP(TM) in a straight line measures both the bigness and number of several classes of lipoprotein particles, including critical risk factors as cited by the National Cholesterol Education Program, giving every accurate assessment of cardiovascular risk.

Statements in this express release that are not strictly historical facts are “forward-looking” statements (identified by the words “believe”, “estimate”, “project”, “expect” or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ importantly from the forward-looking statements. Factors that would cause or contribute to like differences include, but are not limited to, continued acknowledgment of the Company’s products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company’s periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.

This blog found on keywords:

» Filed Under drug test

Comments

Leave a Reply




  • Partner links